725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
Main Authors: | Monika Semmrich, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Mathilda Kovacek, Petra Holmkvist, Carolin Svensson, Therese Blidberg, Carl Roos, Andres McAllister, Mimoza Demiri, Marie Borggren, Ingrid Karlsson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
by: Ingrid Teige, et al.
Published: (2019-03-01) -
Evripid: Ion (725‒1249)
by: Mojca Cajnko
Published: (2016-12-01) -
594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
by: Laetitia Fend, et al.
Published: (2020-11-01) -
Bröstcancerdrabbade kvinnors upplevelse av mötet med sjuksköterskan
by: Demiri, Mimoza, et al.
Published: (2015) -
TNFR2: Role in Cancer Immunology and Immunotherapy
by: Yang Y, et al.
Published: (2021-04-01)